Upstream Bio Inc. (UPB)

NASDAQ: UPB · Real-Time Price · USD

8.86

0.47 (5.60%)

At close: Apr 28, 2025, 3:59 PM

8.20

-7.45%

Pre-market: Apr 29, 2025, 04:06 AM EDT

5.60% (1D)

Bid	8
Market Cap	475.68M
Revenue (ttm)	2.29M
Net Income (ttm)	-52.17M
EPS (ttm)	-5.58
PE Ratio (ttm)	-1.59
Forward PE	n/a
Analyst	Buy

Ask	10.3
Volume	261,897
Avg. Volume (20D)	266,921
Open	8.35
Previous Close	8.39
Day's Range	7.95 - 8.87
52-Week Range	5.14 - 29.46
Beta	0.49

About UPB

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date n/a

Employees 52

Stock Exchange NASDAQ

Ticker Symbol UPB

Website https://upstreambio.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for UPB stock is "Buy." The 12-month stock price forecast is $56.5, which is an increase of 537.70% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+7.83%

Upstream Bio shares are trading lower after the co... Unlock content with Pro Subscription

5 months ago

+8.91%

Upstream shares are trading higher after multiple firms initiated coverage on the stock with an Overweight rating.

News

1 week ago · seekingalpha.com

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

Upstream Bio's IPO raised ~$293m, focusing on developing verekitug, a unique TSLP receptor antagonist for severe respiratory disorders, now in Phase 2 trials. The company has a strong cash position of...